1,8-Cineole / MFN2 Cancer Research Results

1,8-Cin, 1,8-Cineole: Click to Expand ⟱
Features:

1,8-Cineole — 1,8-cineole, also called eucalyptol, is a volatile bicyclic monoterpene ether and major active constituent of eucalyptus oil and several other aromatic plant oils (other plants such as oregano (Origanum spec.), thyme (Thymus spec.), guava (Psidium pohlianum) or sage (Salvia spec.)). Eucalyptus oil used for medicinal applications should contain at least 70% of 1,8-Cineol. It is best classified as a small-molecule phytochemical / essential-oil monoterpenoid rather than as a botanical extract. Its main established human-use identity is respiratory anti-inflammatory / mucolytic support, while its oncology relevance is preclinical and concentration-limited.

Primary mechanisms (ranked):

  1. Apoptosis induction through ↓ Akt / ↓ survivin with ↑ p38 MAPK, ↑ cleaved caspase-3, and ↑ cleaved PARP in colorectal cancer models.
  2. Suppression of PI3K / Akt / mTOR signaling linked to reduced migration and invasion in skin cancer models.
  3. Anti-proliferative and cell-cycle stress effects, including reduced BrdU incorporation and tumor-growth suppression in xenograft models.
  4. Oxidative-stress-linked apoptosis or senescence in selected models; this appears model-dependent and may require high concentrations.
  5. Anti-inflammatory cytokine suppression, including ↓ TNF-α and ↓ IL-1β, which is better established in inflammatory/airway contexts than as a direct cancer mechanism.
  6. Membrane penetration / formulation effects, relevant to delivery and topical/transmucosal exposure but not a cancer-selective mechanism.

Bioavailability / PK relevance: 1,8-cineole is orally and inhalationally absorbed and undergoes rapid systemic distribution, with CYP3A-mediated oxidation as an important metabolic route. Enteric-coated oral preparations can deliver measurable tissue exposure in airway/nasal tissues, but oncology-relevant systemic concentrations are not established.

In-vitro vs systemic exposure relevance: Many anticancer studies use millimolar-range in-vitro concentrations or concentrated essential-oil fractions, which likely exceed routine achievable systemic exposure from conventional oral or inhaled use. Direct cancer-cell effects should therefore be marked as exposure-constrained unless a delivery formulation is specified.

Clinical evidence status: Preclinical oncology only. There is cell-line and animal/xenograft evidence for anticancer activity, but no established cancer-directed clinical efficacy. Human clinical deployment is mainly respiratory/supportive use of eucalyptus oil or purified 1,8-cineole preparations, not antineoplastic therapy.

1,8-Cineole Cancer Mechanism Summary

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Akt / survivin / p38 apoptosis axis ↓ Akt; ↓ survivin; ↑ p38; ↑ cleaved PARP; ↑ caspase-3 Limited direct selectivity data G Apoptosis and tumor-growth suppression Core anticancer mechanism in colorectal cancer models; likely high-concentration dependent.
2 PI3K / Akt / mTOR invasion axis ↓ PI3K; ↓ Akt; ↓ mTOR; ↓ migration; ↓ invasion Not well established G Anti-invasive and anti-metastatic signaling Mechanistically central in skin cancer models; therapeutic translation remains preclinical.
3 Cell proliferation and cell-cycle stress ↓ proliferation; ↓ BrdU incorporation; ↑ growth arrest (model-dependent) Unclear G Cytostatic pressure and reduced tumor expansion Observed across multiple cancer models, but dose ranges often exceed routine clinical exposure.
4 ROS-linked apoptosis or senescence ↑ ROS (model-dependent); ↑ oxidative stress-linked death or senescence May show anti-inflammatory or antioxidant-context effects G Context-dependent oxidative stress leverage Evidence is mixed by model and preparation; stronger when using 1,8-cineole-rich extracts or high concentrations.
5 Inflammatory cytokine signaling Potential ↓ NF-κB-linked inflammatory support (context-dependent) ↓ TNF-α; ↓ IL-1β; ↓ airway inflammatory signaling R/G Anti-inflammatory modulation Better supported for airway/inflammatory disease than for direct cancer-cell killing.
6 Membrane penetration and formulation effects May alter uptake of co-administered compounds (context-dependent) Potential irritation or barrier disruption at high topical exposure R/G Delivery modifier Important for essential-oil and topical/transmucosal contexts; not inherently tumor-selective.
7 CYP3A metabolism and drug-interaction constraint ↔ direct anticancer effect CYP3A-mediated oxidation; systemic clearance R/G PK limitation Potential relevance for co-administered drugs, especially where CYP3A substrates or inhibitors are involved.
8 Clinical Translation Constraint High in-vitro concentrations may not map to systemic dosing GI irritation, CNS toxicity risk in overdose, pediatric laryngospasm/seizure precautions G Translation barrier Oncology status preclinical; established human use is respiratory/supportive rather than antineoplastic.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
MFN2, Mitofusin 2: Click to Expand ⟱
Source:
Type:

MFN1, MFN2, and OPA1 are mostly AD / neurodegeneration-relevant pathway targets: In AD, the general pattern is: fusion proteins MFN1, MFN2, and OPA1 tend to be reduced or functionally impaired, while fission signaling such as DRP1/FIS1 is often increased, contributing to fragmented mitochondria, synaptic injury, oxidative stress, and impaired bioenergetics

MFN1, MFN2, and OPA1 are mitochondrial fusion regulators. MFN1 and MFN2 mediate outer mitochondrial membrane fusion, while OPA1 mediates inner mitochondrial membrane fusion and helps maintain cristae structure. In Alzheimer’s disease and related neurodegenerative models, mitochondrial dynamics are commonly shifted toward excessive fragmentation, with reduced or impaired fusion signaling and increased fission stress. Restoring MFN2/OPA1/MFN1 activity may help preserve mitochondrial network integrity, oxidative phosphorylation, neuronal transport, calcium handling, and synaptic resilience.

Target / Pathway Primary Disease Relevance Normal Function Observed / Suspected Change in AD Therapeutic Direction Database Interpretation Evidence Strength Notes for Product Screening
MFN1 Mostly AD / neurodegeneration; secondary cancer relevance Outer mitochondrial membrane fusion protein. Works with MFN2 to tether and fuse adjacent mitochondria, helping maintain mitochondrial network integrity and mitochondrial DNA/protein complementation. Generally reported as reduced or functionally impaired in AD-related mitochondrial dynamics imbalance, contributing to mitochondrial fragmentation and reduced neuronal bioenergetic resilience. Support / restore mitochondrial fusion where excessive fission and mitochondrial fragmentation are present. Pathway target rather than product. Useful as part of a broader “mitochondrial fusion support” or “anti-fragmentation” pathway entry. Moderate Track products that increase MFN1 expression, improve mitochondrial network morphology, reduce DRP1-driven fragmentation, or restore fusion/fission balance.
MFN2 Strong AD / neurodegeneration relevance; also cancer and metabolic relevance Outer mitochondrial membrane fusion protein. Also involved in mitochondria-ER contact regulation, calcium handling, mitophagy-related quality control, mitochondrial trafficking, and cellular stress adaptation. MFN2 dysfunction or downregulation is associated with impaired mitochondrial fusion, abnormal mitochondria-ER communication, calcium stress, oxidative stress, synaptic vulnerability, and possibly amyloid/tau-associated mitochondrial injury. Usually upmodulation / restoration is desirable in AD models where mitochondrial fragmentation, poor transport, or excessive fission is present. High-priority AD target. Best entered as a mitochondrial dynamics, fusion, ER-mitochondria contact, and mitophagy-quality-control target. Moderate-Strong Track products that increase MFN2, improve mitochondrial elongation, reduce Aβ/tau-induced mitochondrial fragmentation, improve calcium homeostasis, or restore mitochondrial transport in neurons.
OPA1 Strong AD / neurodegeneration relevance; also apoptosis and cancer relevance Inner mitochondrial membrane fusion protein. Maintains cristae structure, supports oxidative phosphorylation, preserves mitochondrial membrane organization, and helps regulate cytochrome-c release during apoptosis. OPA1 loss or cleavage can reduce inner membrane fusion, destabilize cristae, impair oxidative phosphorylation, increase mitochondrial fragmentation, and sensitize neurons to synaptic and metabolic stress. Support / stabilize OPA1 activity, especially long-form fusion-active OPA1, where mitochondrial stress causes excessive OPA1 cleavage and fragmentation. High-priority AD target. Best entered under mitochondrial fusion, cristae integrity, oxidative phosphorylation, and apoptosis-resistance pathways. Moderate-Strong Track products that preserve OPA1, reduce pathological OPA1 cleavage, improve cristae integrity, improve ATP production, or reduce mitochondrial apoptosis signaling.


Scientific Papers found: Click to Expand⟱
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, *antiOx↑, *neuroP↑, *BioAv↑, *Half-Life↝, *toxicity↓, *PGE2↓, *TNF-α↓, *IL1β↓, *NO↓, *NF-kB↓, *PPARγ↓, COX2↓, *ROS↓, *SOD↑, *Catalase↑, *TAC↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *NADPH↑, *GPx↑, *AntiBio↑, *eff↑, *AntiFungal↑, *AntiViral↑, *TRPA1↑, eff↑, TumCCA↑, ROS↑, MAPK↝, mTOR↝, Apoptosis↑, survivin↓, Akt↓, p38↑, cl‑PARP↑, cl‑Casp3⇅, P53↑, BAX↑, Cyt‑c↑, Casp9↑, Dose↝, *Aβ↓, *tau↓, *GSK‐3β↓, *BACE↓, *cardioP↑, MFN2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

MFN2↑, 1,  

Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3⇅, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   MAPK↝, 1,   p38↑, 1,   survivin↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiBio↑, 1,   TRPA1↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis ⓘ

NADPH↑, 1,   PPARγ↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,  
Total Targets: 32

Scientific Paper Hit Count for: MFN2, Mitofusin 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:409  Target#:1490  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page